San Diego-based synthetic biology player Synthorx Inc. has landed $63 million in series C financing to back further advancement of a series of improved cytokine therapies, led by Synthorin IL-2, an interleukin-2 tuned specifically for activity on certain immune cells. Following a pre-investigational new drug (IND) meeting with the FDA, the company expects to file an IND in the first half of 2019, Laura Shawver, the company's president and CEO, told BioWorld.